


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number: WO 98/16505 (43) International Publication Date: 23 April 1998 (23.04.98)
C07C 311/13, 311/24, 311/06, 311/10, C07K 5/062, 5/072, C07D 217/24, A61K 31/18		
(21) International Application Number: PCT/US97/18396		(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.
(22) International Filing Date: 9 October 1997 (09.10.97)		
(30) Priority Data: 60/028,313 11 October 1996 (11.10.96) US		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [-US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): ALBRECHT, Hans, P. [DE/DE]; Am Wetzelsberg 59, D-69517 Goxheimertal (DE). ALLEN, Hamish, John [GB/US]; 47 Eastern Point Drive, Shrewsbury, MA 01545 (US). BRADY, Kenneth, Dale [US/US]; 32 Ivernia Road, Worcester, MA 01606 (US). HARTER, William, Glen [US/US]; 3750 Shagbark, Chelsea, MI 48118 (US). KOSTLAN, Catherine, Rose [US/US]; 9876 Moon Road, Saline, MI 48176 (US). ROTH, Bruce, David [US/US]; 49255 Hunt Club Court, Plymouth, MI 48170 (US). WALKER, Nigel [GB/DE]; Frauenpfad 20, D-69221 Dossenheim (DE).		

(54) Title: SULFONAMIDE INTERLEUKIN-1 β CONVERTING ENZYME INHIBITORS

(57) Abstract

The present invention relates to compounds that are inhibitors of interleukin-1 β converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 β converting enzyme.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

SULFONAMIDE INTERLEUKIN-1 β CONVERTING ENZYME INHIBITORS

FIELD OF THE INVENTION

This invention relates to compounds that are inhibitors of interleukin-1 β converting enzyme. This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, and inflammatory diseases and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 β converting enzyme (Caspase-1).

BACKGROUND OF THE INVENTION

The compounds of the present invention are inhibitors of interleukin-1 β converting enzyme (ICE) and are useful in treating diseases in which interleukin-1 plays a role.

ICE acts on pro-interleukin-1 β (pro-IL-1 β) to produce interleukin-1 β (IL-1 β), which is an inflammatory cytokine. In addition, ICE (Caspase-1) regulates at least four cytokines. ICE activates IL- β and IL-18, and indirectly regulates the production of IL-1 α and IFN γ . Several diseases are associated with excessive interleukin-1 activity. Examples of diseases in which interleukin-1 is involved include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and neuroinflammatory disorders such as stroke. Other diseases include septic shock, reperfusion injury, Alzheimer's disease, and shigellosis.

Agents that modulate IL-1 β activity have been shown to have beneficial in vivo effects. For example, compounds that are interleukin-1 receptor antagonists have been shown to inhibit ischemic and excitotoxic damage in rat brains. See, for example, Relton J.K., et al., Brain Research Bulletin, 1992;29:243-246. Additionally, ICE inhibitors were shown to reduce

-2-

inflammation and pyrexia in rats. See Elford P.R., et al., British Journal of Pharmacology, 1995;115:601-606.

The compounds of the present invention are also inhibitors of other cysteine proteases in the ICE family. Many of these proteases have only recently been described in the literature. While the nomenclature is still unresolved, the following proteases are representative members of this class of enzymes; Ich-2 (also called Tx or ICErel-II), ICErel-III, Ich-I (also called Nedd-2), CPP-32 (also called apopain and yama), Mch-2, Mch-3 (also called ICE-lap3, CMH-1), and Ced-3. See Henkart P.A., Immunity, 1996;4:195-201. It is recognized that members of this enzyme family play key biological roles in both inflammation and apoptosis (programmed cell death). In particular, Caspase-4 can activate IL-1 β and IL-18. It has been shown that a murine homolog of Caspase-4 can activate ICE. Thus, inhibition of Caspase-4 will act to inhibit ICE. See Thornberry N.A., et al., Perspectives in Drug Discovery and Design, 1994;2:389-399.

In addition to its effects on IL-1 β production, ICE has been shown to play a role in the production of the inflammatory mediator interferon- γ (Ghayur, et al., Nature, 1997;386(6625):619-623). ICE processes the inactive proform of interferon- γ inducing factor (IGIF; Interleukin-18) to active IGIF, a protein which induces production of interferon- γ by T-cells and natural killer cells. Interferon- γ has been implicated in the pathogenesis of diseases such as inflammatory disorders and septic shock. Therefore, ICE inhibitors would be expected to have beneficial effects in such disease states by effects on interferon- γ .


Recently, the nomenclature of these cysteine proteases in the ICE family (also known as Caspases with ICE being known as Caspase-1) has been further defined. The following proteases are representative members of this class of enzymes using the nomenclature described in Alnemri, et al., Cell, 1996;87:171: Caspase-2 (also known as Ich-1); Caspase-3 (also known as CPP32, Yama, and apopain); Caspase-4 (also known as TX, Ich-2, and ICE rel-II); Caspase-5 (also known as ICE rel-III); Caspase-6 (also known as Mch2); Caspase-7 (also known

-3-


as Mch3); Caspase-8 (also known as FLICE and Mch5); Caspase-9 (also known as ICE-LAP6 and Mch6); Caspase-10 (also known as Mch4).

SUMMARY OF THE INVENTION

The present invention provides compounds of Formula I



wherein R^1 is



R^3 is hydrogen,

C₁-C₆ alkyl,

10 -(CH₂)_n aryl, or

$-(CH_2)_n$ heteroaryl;

R⁴ is C₁-C₆ alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

-4-

R^5 and R^6 are each independently hydrogen,

C_1 - C_6 alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

5 R^7 is C_1 - C_6 alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

each n is independently 0 to 6;




each m is independently 0, 1, 2, or 3;

10 A is alanine, leucine, isoleucine, proline, phenylalanine, glycine, tyrosine, serine, threonine, tryptophan, cysteine, methionine, valine, asparagine, glutamine, aspartic acid, lysine, glutamic acid, arginine, or histidine;

each R^Q is independently hydrogen or C_1 - C_6 alkyl;

R^2 is $-(CH_2)_n-Z$; and


15 Z is aryl, heteroaryl, cycloalkyl, C_1 - C_6 alkyl, ,




fluorenyl, substituted fluorenyl, substituted aryl,
substituted heteroaryl, or substituted cycloalkyl, and the pharmaceutically
acceptable salts, esters, amides, and prodrugs thereof.

-5-

In a preferred embodiment of the compounds of Formula I, R¹ is




In another preferred embodiment of the compounds of Formula I, R¹ is



5 m is 0, and R⁷ is -(CH₂)_n aryl.

In another preferred embodiment of the compounds of Formula I, R¹ is




m is 0, and R⁷ is -CH₂ aryl.

10 In another preferred embodiment of the compounds of Formula I, R² is -(CH₂)_n aryl.


In another preferred embodiment of the compounds of Formula I, aryl is phenyl or naphthyl.

In another preferred embodiment of the compounds of Formula I, R² is -(CH₂)_n-cycloalkyl.

15 In another preferred embodiment of the compounds of Formula I, R¹ is




In another preferred embodiment of the compounds of Formula I, R² is




-6-

In another preferred embodiment of Formula I, R² is



The present invention also provides compounds of the Formula I





I

wherein R² is -CH₂CH₂- aryl, -CH₂- cycloalkyl, -CH₂CH₂- cycloalkyl, or

5 -CH₂CH₂- heteroaryl;

R¹ is



R^a is -(CH₂)_n- aryl or -(CH₂)_n heteroaryl;

R^b is aryl or heteroaryl;


10 R^c is -CH₂ aryl or aryl;

R^d is hydrogen or C₁-C₆ alkyl;


R^e is -CH₂ aryl or -CH₂ heteroaryl; and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

-7-

In a preferred embodiment of the compounds of Formula I, R¹ is



In another preferred embodiment of the compounds of Formula I, R¹ is



- 5 In another preferred embodiment of the compounds of Formula I, R^e is
-(CH₂)_n aryl.

In another preferred embodiment of the compounds of Formula I, aryl is phenyl or naphthyl.

- 10 In another preferred embodiment of the compounds of Formula I, R^b is
aryl.

In a preferred embodiment, the present invention provides the compounds:

- 15 3-Benzylloxycarbonylamino-4-oxo-5-(2-phenylethanesulfonylamino)-pentanoic acid;
 3-Benzylloxycarbonylamino-4-oxo-5-(3-phenyl-propane-1-sulfonylamino)-pentanoic acid;
 3-Benzylloxycarbonylamino-4-oxo-5-phenylmethanesulfonyl-amino-pentanoic acid;
 5-Benzenesulfonylamino-3-benzylloxycarbonylamino-4-oxo-pentanoic acid;
20 3-Benzylloxycarbonylamino-5-methanesulfonylamino-4-oxo-pentanoic acid;
 3-Benzylloxycarbonylamino-5-(naphthalene-1-sulfonylamino)-4-oxo-pentanoic acid;
 3-Benzylloxycarbonylamino-5-(2-cyclohexyl-ethanesulfonylamino)-4-oxo-pentanoic acid;
25 3-Benzylloxycarbonylamino-5-(2-naphthalen-1-yl-ethanesulfonylamino)-4-oxo-pentanoic acid;

-8-

- 3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(R)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-Benzylloxycarbonylamino-5-(indan-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 5 3-Benzylloxycarbonylamino-5-(9-fluoro-9H-fluoren-9-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 10 3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 3-[2-(2-Benzylloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl-butyrylamino}-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 15 3-(2-{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxy-butyrylamino}-3-methyl-butyrylamino)-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 20 3-(2-Acetylamino-propylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 25 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl-butyrylamino}-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-(2-{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxy-butyrylamino}-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 30 3-(2-{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxy-butyrylamino}-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;

-9-

3-[2-(2-Benzylloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;

- 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetanino-5-
5 benzenesulfonylamino-4-oxo-pentanoic acid;
(S)-5-(Bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-3-[2-(1-oxo-
3,4-dihydro-1H-isoquinolin-2-yl)-acetyl amino]-pentanoic acid;
(S)-4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetyl amino]-5-
10 (2-phenyl-ethanesulfonylamino)-pentanoic acid; and
4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetyl amino]-5-
phenylmethanesulfonylamino-pentanoic acid.

Also provided is a method of inhibiting interleukin-1 β converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-1 β converting enzyme a therapeutically effective amount of a compound of Formula I or II.

Also provided is a method of inhibiting Caspase-4, the method comprising administering to a patient in need of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Formula I or II.

Also provided is a method of treating stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Formula I or II.

Also provided is a method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Formula I or II.

25 In a preferred embodiment, the inflammatory disease is arthritis.

In another preferred embodiment, the inflammatory disease is inflammatory bowel disease.

Also provided is a pharmaceutically acceptable composition that contains a compound of Formula I or II.

-10-


Also provided is a method of treating septic shock, the method comprising administering to a patient having septic shock a therapeutically effective amount of a compound of Formula I or II.

5 Also provided is a method of treating reperfusion injury, the method comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Formula I or II.

Also provided is a method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Formula I or II.



10 Also provided is a method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Formula I or II.

The present invention provides compounds of the Formula II



15 wherein

R¹ is



R^a is -(CH₂)_n- aryl or -(CH₂)_n heteroaryl;

R^b is aryl or heteroaryl;


-11-

R^c is $-\text{CH}_2$ aryl or aryl;


R^d is hydrogen or $C_1\text{-}C_6$ alkyl;

R^e is $-\text{CH}_2$ aryl or $-\text{CH}_2$ heteroaryl; and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

5 In a preferred embodiment of the compounds of Formula II, R^1 is



In a preferred embodiment of the compounds of Formula II, R^1 is



In another preferred embodiment of the compounds of Formula II, R^e is

10 $-(\text{CH}_2)_n$ aryl.

In another preferred embodiment of the compounds of Formula II, aryl is phenyl or naphthyl.

In another preferred embodiment of the compounds of Formula II, R^b is aryl.

15

DETAILED DESCRIPTION OF THE INVENTION

The term "alkyl" means a straight or branched chain hydrocarbon.

Representative examples of alkyl groups are methyl, ethyl, propyl, isopropyl, isobutyl, butyl, tert-butyl, sec-butyl, pentyl, and hexyl.

The term "cycloalkyl" means a cyclic alkyl group having 3 to 8 carbons.

20

The cycloalkyl group can be fused to one or more aryl or heteroaryl groups.

Representative examples are cyclopentyl, cyclohexyl, 1- or 2-indanyl, 1- or 2-tetralinyl, and 9-fluorenyl. The term "cycloalkyl" includes bicycloalkyl and substituted bicycloalkyl. Suitable substituents are defined with respect to aryl below.

-12-

The term "alkoxy" means an alkyl group attached to an oxygen atom.

Representative examples of alkoxy groups include methoxy, ethoxy, tert-butoxy, propoxy, and isobutoxy.

The term "halogen" includes chlorine, fluorine, bromine, and iodine.

5 The term "aryl" means an aromatic hydrocarbon. Representative examples of aryl groups include phenyl, naphthyl, and biphenyl.

The term "heteroatom" includes oxygen, nitrogen, sulfur, and phosphorus.

10 The term "heteroaryl" means an aryl group wherein one or more carbon atom of the aromatic hydrocarbon has been replaced with a heteroatom. Examples of heteroaryl groups include furan, thiophene, pyrrole, thiazole, pyridine, pyrimidine, pyrazine, benzofuran, indole, coumarin, quinoline, isoquinoline, carbazole, and naphthyridine.

15 The aryl or heteroaryl groups may be substituted with one or more substituents, which can be the same or different. Examples of suitable substituents include alkyl, alkoxy, thioalkoxy, hydroxy, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, -(CH₂)_nOH, -NO₂, -CN, -CO₂H, -CO₂alkyl, -SO₃H, -CHO, -COalkyl, -CONH₂, -CONH-alkyl, -CONHR^q, -CON(alkyl)₂, -(CH₂)_n-NH₂, -(CH₂)_n-NH-alkyl, -NHR^q, or -NHCOR^q, where n is 1 to 5 and R^q is hydrogen or alkyl. It is intended that the terms "aryl" and "heteroaryl" include unsubstituted as well as substituted aryl and heteroaryl groups. It is also intended that the substituents on the aryl or heteroaryl groups include other cyclic compounds that are fused to the aryl or heteroaryl groups, typically by adjacent carbon atoms. For example, a phenyl group may be fused with a cyclohexane group.

25 The symbol "-" means a bond.

30 The compounds of Formula I or II can be administered to a patient either alone or as part of a pharmaceutically acceptable composition. The compositions can be administered to patients such as humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments or drops), or as a buccal or nasal spray.

-13-

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid

-14-

polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.

5 Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part
10 of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,
20 dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these substances, and the like.

25 Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying, and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide,
30 bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable

-15-

non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.

5 Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being 10 within the scope of this invention.

The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 15 0.01 to about 100 mg/kg of body weight per day is preferable. The specific dosage used, however, can vary. For example, the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.

20 The term "pharmaceutically acceptable salts, esters, amides, and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, 25 commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by 30 separately reacting the purified compound in its free-base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate,

-16-

oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. These may include cations based on the alkali and alkaline earth metals, such as 5 sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, Berge S.M., et al., "Pharmaceutical Salts," J. Pharm. Sci., 10 1977;66:1-19 which is incorporated herein by reference.)

Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C₁-C₆ alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C₅-C₇ cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C₁-C₄ alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C₁-C₆ alkyl amines, and secondary C₁-C₆ dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C₁-C₃ alkyl primary amines, and C₁-C₂ dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.

The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of 30 which are incorporated herein by reference.

-17-

In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

5 The compounds of the present invention can exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compounds; ie, each asymmetric carbon can have either the R or S configuration. It is contemplated that all stereoisomeric forms of the compounds as well as mixtures thereof, including racemic mixtures, form part of this invention.

10 The compounds of the present invention are administered to a patient in need of ICE inhibition. In general, patients in need of ICE inhibition are those patients having a disease or condition in which interleukin-1 plays a role. Examples of such diseases include, but are not limited to, inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and neuroinflammatory 15 disorders such as stroke and septic shock. Other diseases include reperfusion injury, Alzheimer's disease, and shigellosis.


A "therapeutically effective amount" is an amount of a compound of Formula I or II that when administered to a patient having a disease that can be treated with a compound of Formula I or II ameliorates a symptom of the disease. 20 A therapeutically effective amount of a compound of Formula I or II is readily determined by one skilled in the art by administering a compound of Formula I or II to a patient and observing the results.

25 The following examples illustrate particular embodiments of the invention and are not intended to limit the scope of the specification and claims in any manner.

Compounds of the current invention can be prepared generally by converting the appropriate starting sulfonamide 1 to Boc sulfonamide 2 using a reagent such as di-tert-butyl dicarbonate. Boc sulfonamide 2 may then be reacted with the appropriately substituted aspartic acid bromomethylketone β tert-butyl ester 3 in the presence of a base, followed by treatment with acid to give the desired product 4.

-18-

Scheme 1




-19-

Alternatively, compounds of the current invention can be prepared generally by reaction of the appropriately substituted aspartic acid aldehyde 1 with nitromethane in the presence of a base such as potassium tert-butoxide to give nitro alcohol 2. Reduction of 2 to the amine 3, followed by reaction with the appropriate sulfonyl chloride gives 4 which may be oxidized to the ketone 5 with a reagent such as Dess Martin periodinane or by a Swern oxidation. Acidic deprotection of the t-butyl ester with HCl or trifluoroacetic acid gives the desired product 6.

-20-

Scheme 2



EXAMPLE 1a

1,1-Dimethylethyl [(2-phenylethyl)sulfonyl]carbamate

A solution of di-tert-butylidicarbonate (1.07 g) in methylene chloride (3 mL) was added dropwise to a solution of 2-phenylethanesulfonamide (0.78 g),
5 triethylamine (0.48 g), and DMAP (dimethylamino-pyridine) (0.012 g) in methylene chloride (10 mL). The reaction mixture was stirred for 3 hours at ambient temperature and the solvent was evaporated. The resulting oil was taken up in ethyl acetate, washed with 5% HCl, water, and then brine. The organic layer was dried over sodium sulfate, filtered, and the solvent evaporated. The resulting
10 oil was purified by flash column chromatography on silica (1% ether/10% hexane/methylene chloride gradient to 20% ether/10% hexane/methylene chloride) to yield 1,1-dimethylethyl [(2-phenylethyl)sulfonyl]carbamate (0.87 g), melting point (mp) 99-102°C, which was used in the next step without further purification.

15 The following compounds were prepared according to the procedure of Example 1a from the corresponding sulfonamides:

EXAMPLE 1b

1,1-Dimethylethyl [(3-phenylpropyl)sulfonyl]carbamate, mp 59-62°C.

EXAMPLE 1c

1,1-Dimethylethyl [(phenylmethyl)sulfonyl]carbamate, mp 90-94°C (dec).

20

EXAMPLE 1d

Tert-butyl[benzenesulfonyl]carbamate

MS (AP-): 256.

CHN Calculated: C, (51.35%); H, (5.88%); N, (5.44%); S, (12.46%).

Found: C, (51.41%); H, (5.59%); N, (5.40%); S, (12.44%).

-22-

EXAMPLE 1e

Tert-butyl[methanesulfonyl]carbamate

MS (AP-): 194.

CHN Calculated: C, (36.91%); H, (6.71%); N, (7.17%); S, (16.42%).

5 Found: C, (36.96%); H, (6.54%); N, (7.08%); S, (16.39%).

EXAMPLE 1f

Tert-butyl[naphthalene-1-sulfonyl]carbamate

MS (AP-): 306.

CHN Calculated: C, (58.62%); H, (5.57%); N, (4.56%); S, (10.43%).

10 Found: C, (58.54%); H, (5.40%); N, (4.44%); S, (10.40%).

EXAMPLE 1g

Tert-butyl[2-cyclohexyl-ethanesulfonyl]carbamate

MS (AP-): 290.

CHN Calculated: C, (53.58%); H, (8.65%); N, (4.81%); S (11.00%).

15 Found: C, (53.64%); H, (8.58%); N, (4.89%); S (11.26%).

EXAMPLE 1h

Tert-butyl[2-naphthalen-1-yl-ethanesulfonyl]carbamate

NMR (CDCl₃): 7.98 (d, 1H), 7.89 (d, 1H), 7.79 (d, 1H), 7.6-7.3 (m, 4H), 6.85 (br, 1H), 3.83-3.77 (m, 2H), 3.64-3.60 (m, 2H), 1.44 (s, 9H).

20

EXAMPLE 1i

Tert-butyl[7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonyl]carbamate

MS (AP+): base peak 276 (parent with loss of isobutylene).

CHN Calculated: C, (54.36%); H, (7.60%); N, (4.23%).

Found: C, (54.64%); H, (7.62%); N, (3.98%).

-23-

EXAMPLE 1j

Tert-butyl[indan-1-ylmethanesulfonyl]carbamate

IR (cm^{-1}): 3246, 3232, 2980, 2937, 1740, 1436, 1350, 1243, 1137, 9176,
830, 757.

5 MS (AP+): 310.

EXAMPLE 1k

Tert-butyl[9-fluoro-9H-fluoren-9-ylmethanesulfonyl]carbamate

MS (AP-): 376.

CHN Calculated: C, (60.46%); H, (5.34%); N, (3.71%); S, (8.50%); F, (5.03%).

10 Found: C, (60.19%); H, (5.40%); N, (3.64%); S, (8.33%); F, (4.89%).

EXAMPLE 2a

3-Benzylloxycarbonylamino-4-oxo-5-(2-phenylethane-sulfonylamino)-pentanoic acid

To a solution of 1,1-dimethylethyl [(2-phenylethyl)sulfonyl]carbamate
15 (0.28 g) in dry DMF (dimethylformamide) (2 mL) was added potassium
tert-butoxide (0.12 g) and the resulting solution was added dropwise to an ice-
cooled solution of 3-benzylloxycarbonylamino-5-bromo-4-oxo-pentanoic acid
1,1-dimethylethyl ester (0.32 g) in DMF (2 mL). The reaction mixture was stirred
at room temperature for 24 hours, poured into water (100 mL), and the resulting
20 solution was neutralized with dilute aqueous NH_4Cl . The product was extracted
into ether (3×50 mL) and the combined organic layers were washed with water,
dilute $\text{Na}_2\text{S}_2\text{O}_3$, and then brine. The solution was dried over sodium sulfate,
filtered, and the solvent was evaporated to give the crude intermediate ester
(0.49 g) as a yellow oil.

25 The oil was dissolved in methylene chloride (10 mL) and trifluoroacetic
acid (10 mL) and the resulting solution was stirred at room temperature for
6 hours. The solvent was evaporated to give a yellow oil which was purified by
column chromatography (silica; 1% acetone/1% formic acid/methylene chloride
gradient to 20% acetone/1% formic acid/methylene chloride) and recrystallized

-24-

from ether/hexane to give 3-benzyloxycarbonylamino-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid (0.04 g), mp 100-101°C.
(NMR [CD₃OD], ppm) 7.4-7.1 (m, 10H), 5.1 (s, 2H), 4.5 (t, 1H), 4.35 (d, 1H), 4.15 (d, 1H), 3.3-3.0 (m, 4H), 2.9-2.7 (m, 2H).

5 The following compounds were prepared according to the procedure of Example 2a from the corresponding Boc protected sulfonamides:

EXAMPLE 2b

3-Benzylcarbonylamino-4-oxo-5-(3-phenylpropane-1-sulfonylamino)-pentanoic acid, mp 96-104°C.

10 (NMR [CD₃OD], ppm) 7.4-7.1 (m, 10H), 5.11 (s, 2H), 4.5 (t, 1H), 4.3 (d, 1H), 4.1 (d, 1H), 3.05-2.6 (m, 6H), 2.2-2.0 (m, 2H).

EXAMPLE 2c

3-Benzylcarbonylamino-4-oxo-5-phenylmethanesulfonyl-amino-pentanoic acid, mp 160-164°C.

15 (NMR [CD₃OD], ppm) 7.5-7.2 (m, 10H), 5.13 (s, 2H), 4.47 (t, 1H), 4.30 (s, 2H), 4.20 (d, 1H), 4.0 (d, 1H), 2.9-2.7 (m, 2H).

EXAMPLE 2d

5-Benzenesulfonylamino-3-benzyloxycarbonylamino-4-oxo-pentanoic acid

MS (AP+): 421.

20 CHN Calculated: C, (54.28%); H, (4.79%); N, (6.66%); S, (7.63%).

Found: C, (54.19%); H, (4.85%); N, (6.47%); S, (7.36%).

Water (0.10%).

EXAMPLE 2e

3-Benzylcarbonylamino-5-methanesulfonylamino-4-oxo-pentanoic acid

25 NMR (ppm, CD₃OD): 7.4-7.2 (m, 5H), 5.48 (s, 2H), 4.51 (t, 1H), 4.4-4.1 (dd, 2H), 2.9-2.7 (m, 5H).

-25-

CHN Calculated: C, (53.58%); H, (8.65%); N, (4.81%); S, (11.00%).

Found: C, (53.64%); H, (8.58%); N, (4.89%); S, (11.26%).

EXAMPLE 2f

3-Benzylloxycarbonylamino-5-(naphthalene-1-sulfonylamino)-4-oxo-pentanoic acid

MS (AP+): 471.

IR (KBr, cm⁻¹): 3347, 2928, 1717, 1508, 1327, 1162, 1134, 772, 589.

EXAMPLE 2g

3-Benzylloxycarbonylamino-5-(2-cyclohexyl-ethanesulfonylamino)-4-oxo-pentanoic acid

NMR (ppm, CD₃OD): 7.4-7.2 (m, 5H), 5.12 (s, 2H), 4.50 (t, 1H), 4.4-4.2 (d, 1H), 4.2-4.0 (d, 1H), 3.1-2.7 (m, 4H), 1.8-1.6 (m, 8H), 1.4-1.1 (m, 5H), 1.0-0.8 (m, 2H).

EXAMPLE 2h

3-Benzylloxycarbonylamino-5-(2-naphthalen-1-yl-ethanesulfonylamino)-4-oxo-pentanoic acid

NMR (ppm, CD₃OD) 8.11 (d, 1H), 7.88 (d, 1H), 7.77 (d, 1H), 7.6-7.2 (m, 9H), 5.06 (s, 2H), 4.51 (t, 1H), 4.4 (d, 1H), 4.2 (d, 1H), 3.7-3.5 (m, 2H), 3.4-3.3 (m), 2.9-2.7 (m, 2H).

IR (KBr, cm⁻¹): 3307, 2926, 1735, 1685, 1544, 1398, 1322, 1275, 1136, 778, 698.

EXAMPLE 2i

3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(R)-ylmethanesulfonylamino)-4-oxo-pentanoic acid

IR (LF+CHCl₃, cm⁻¹): 3314, 2960, 1730.5, 1525, 1329, 1217, 1146, 1052, 754.

NMR (CD₃OD, ppm): 7.4-7.2 (m, 5H), 5.12 (s, 2H), 4.5 (t, 1H), 4.4 (d, 1H), 4.15 (d, 1H), 3.45 (d, 1H), 3.0 (d, 1H), 2.9-2.6 (m, 2H), 2.5-2.3 (m, 2H), 2.2-1.8 (m, 3H), 1.8-1.6 (m, 1H), 1.5-1.4 (m, 1H), 1.06 (s, 3H), 0.87 (s, 3H).

-26-

EXAMPLE 2j

3-Benzylloxycarbonylamino-5-(indan-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid

IR (KBr, cm⁻¹): 3314, 2930, 1704, 1530, 1318, 1266, 1145, 1059, 746, 698.

5 MS (AP+): 475.

EXAMPLE 2k

3-Benzylloxycarbonylamino-5-(9-fluoro-9H-fluoren-9-ylmethanesulfonylamino)-4-oxo-pentanoic acid

MS (AP+): 521 (parent with loss of F-).

10 NMR (F19, CD₃OD, ppm) -77.1.

EXAMPLE 2l

3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid

MS (AP-): 493.

15 IR (KBr, cm⁻¹): 3374, 2961, 1733, 1522, 1455, 1416, 1330, 1274, 1204, 1179, 1146, 1052, 698.

EXAMPLE 2m

(R)-3-Benzylloxycarbonylamino-5-(7,7-dimethyl-bicyclo[2.2.1]hept-1-ylmethane-sulfonylamino)-4-oxo-pentanoic acid

20 MS (APCI-): 479.2

The following compounds were prepared according to the procedure of Example 2a from the corresponding di, tri or tetrapeptide bromomethylketones and tert-butyl[(2-phenylethyl)sulfonyl]carbamate:

EXAMPLE 3a

25 3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid

-27-

Calculated for C₂₉H₃₈N₄O₉S₁•0.33 CF₃COOH: C, 54.26; H, 5.88; N, 8.53.

Found: C, 54.26; H, 5.93; N, 8.55.

EXAMPLE 3b

3-[2-(2-Benzylloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl-
butyrylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid

EXAMPLE 3c

3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl-
butyrylamino}-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid

Calculated for C₃₂H₄₂N₄O₁₀S₁•0.24 CF₃COOH: C, 55.56; H, 6.06; N, 7.98.

10 Found: C, 55.56; H, 6.23; N, 8.07.

EXAMPLE 3d

3-(2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxy-
butyrylamino)-3-methyl-butyrylamino)-4-oxo-5-(2-phenyl-ethanesulfonylamino)-
pentanoic acid

15 The following compounds were prepared according to the procedure of Example 2a from the corresponding protected di, tri or tetrapeptide bromomethylketones and tert-butyl[7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonyl]carbamate:

EXAMPLE 4a

20 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-
bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid

MS (AP+): 502.

IR (KBr, cm⁻¹): 3338, 2965, 1738, 1653, 1540, 1395, 1328, 1148.

-28-

EXAMPLE 4b

3-(2-Acetylamino-propylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid

MS (AP-): 472.

5

EXAMPLE 4c

3-[2-(2-Benzylcarbamoyl)-3-methyl-butylamino]-propionylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid

Calculated for C₃₁H₄₄N₄O₁₀S₁•0.30 CF₃COOH: C, 54.31; H, 6.39; N, 8.02.

10 Found: C, 54.31; H, 6.51; N, 7.80.

EXAMPLE 4d

3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methylbutyrylamino}-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid

15 Calculated for C₃₄H₄₈N₄O₁₁S₁•0.43 CF₃COOH: C, 54.36; H, 6.34; N, 7.27.

Found: C, 54.36; H, 6.57; N, 7.35.

EXAMPLE 4e

3-(2-{2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxybutyrylamino}-3-methyl-butylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid

20


EXAMPLE 4f

3-[2-(2-Benzylcarbamoyl)-4-carboxy-butylamino]-3-methylbutyrylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid

25

The compounds of the present invention can also be synthesized by the following route:

-29-



EXAMPLE 5a

3-(1,2,3,4,-Tetrahydro-1-oxo-isoquinoline-2-yl)acetamino-5-benzenesulfonyl
amino-4-oxo-pentanoic acid

5 Step A

To a solution of (1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)acetic acid (2.7 g, 13.0 mMol) prepared according to the procedure of Anderson W.K., et al., *J. Med. Chem.*, 1988;31:2097 and H-Asp (OtBu)OMe × HCl (2.9 g, 12.0 mMol) in dimethylformamide (40 mL) was added at 0°C 1-ethyl-3-(3'-dimethylamino-propyl) carbodiimide × HCl (2.5 g, 13.0 mMol) and triethylamine (4.05 g, 40 mMol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate. The organic phase was washed successively with aqueous sodium hydrogen-carbonate and water, dried over sodium sulfate, and concentrated to give 4.5 g of an amorphous residue.

The residue was dissolved in 40 mL of dioxane/water (1:1) and hydrolyzed in the presence of thymolphthalein by dropwise addition of 1N NaOH (12.0 mL). After evaporation of most of the dioxane and dilution with water the aqueous

-30-

solution was extracted with ether, acidified with dilute HCl to pH 2-3, and the product extracted into ethyl acetate. The organic phase was washed with water, dried over sodium sulfate, and concentrated under reduced pressure to give 3.4 g of crystalline N-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetyl aspartic acid,
5 4-tert-butyl ester.

Step B

To a solution of N-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetyl aspartic acid, 4-tert-butyl ester (3.1 g, 8.25 mMol) in 50 mL of tetrahydrofuran was added at -5°C N-methylmorpholine (1.25 mL, 11.0 mMol) and
10 isobutylchloroformate (1 eq). After 15 minutes between -5°C and 0°C the formed mixed anhydride was added at -78°C to a suspension of sodium borohydride (0.75 g, 20 mMol) in 45 mL of tetrahydrofuran and 15 mL of methanol. After 2 hours at -40°C the reaction was quenched by addition of 5.0 mL of acetic acid. Ethyl acetate/hexane (250 mL, 1:1) and water 30 mL was added. The organic
15 phase was washed successively with saturated aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated under reduced pressure. Purification of the residue over silica (elution with dichloromethane/methanol 20:1) gave 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-4-hydroxy-pentanoic acid, tert-butyl ester (2.3 g).

20 Step C

To a solution at -45°C under nitrogen of dimethylsulfoxide (3.72 mL, 52.4 mMol) in dichloromethane was added dropwise via syringe oxalyl chloride (2.5 g, 28.8 mMol) followed by N-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-4-hydroxy-pentanoic acid, tert-butyl ester (6.88 g, 24.0 mMol). After
25 30 minutes the reaction was quenched by addition of diisopropylethyl amine (12.4 mL, 72.0 mMol) and partitioned between ethyl acetate (800 mL) and water (80 mL). The organic phase was washed successively with 1N sodium hydrogen sulfate and water, dried over sodium sulfate, and concentrated under reduced

-31-

pressure to give 4.8 g of 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-4-oxo-pentanoic acid, tert-butyl ester.

Step D

To 1.15 g (10.0 mMol) of KOtBu (potassium tertbutoxide) in
5 dimethylformamide (30 mL) at 0°C under nitrogen and nitromethane (1.75 mL,
32.5 mMol) was added 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
4-oxo-pentanoic acid, tert-butyl ester (3.6 g, 10.0 mMol). After 3 hours at 0°C the
reaction was quenched by addition of 1.5 mL of acetic acid and partitioned
between ethyl acetate (200 mL) and water (20 mL). The organic phase was washed
10 with saturated aqueous sodium hydrogen carbonate and water, dried over sodium
sulfate, and concentrated under reduced pressure. Purification of the residue over
silica (elution with dichloromethane/methanol 20:1) gave 2.7 g of
3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-4-hydroxy-5-nitro-
pentanoic acid, tert-butyl ester as 1:1 mixture of diastereomers.

15 Step E

A mixture of 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
4-hydroxy-5-nitro-pentanoic acid, tert-butyl ester (2.55 g, 6.05 mMol) and 10% Pd
on charcoal (1.5 g) in 100 mL of methanol containing 5 mL of 10% aqueous acetic
acid was hydrogenated at room temperature for 4 hours. Filtration and evaporation
20 of the solvent under reduced pressure gave of 3-(1,2,3,4-tetrahydro-1-oxo-
isoquinoline-2-yl)-acetamino-5-amino-4-hydroxy-pentanoic acid, tert-butyl ester
hydroacetate (2.7 g).

Step F

To a solution of 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
25 5-amino-4-hydroxy-pentanoic acid, tert-butyl ester hydroacetate (1.31 g,
2.9 mMol) in 15 mL of dichloromethane at 0°C was added
benzenesulfonylchloride (0.45 mL, 3.5 mMol) followed by dropwise addition of
N-methylmorpholine (0.8 mL, 9 mMol). The solution was left at room
temperature for 16 hours, then diluted with ethyl acetate (100 mL). The organic

-32-

phase was washed successively with sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated under reduced pressure. Chromatography over silica (elution with dichloromethane/methanol 15:1) gave
3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
5 5-benzenesulfonylamino-4-hydroxy-pentanoic acid, tert-butyl ester (1.05 g).

Step G

To 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
5-benzenesulfonylamino-4-hydroxy-pentanoic acid, tert-butyl ester (0.9 g,
1.7 mMol) in 20 mL of dichloromethane was added 1.1.1-triacetoxy-1.1-dihydro-
10 1.2-benziodoxol-3-(1H)-one (Dess Martin periodinane, 1.08 g, 2.5 mMol). After
2 hours at room temperature the reaction mixture was diluted with ether, filtered,
washed with sodium hydrogen carbonate and water, dried over sodium sulfate, and
concentrated under reduced pressure. Chromatography over silica (elution with
dichloromethane/methanol 15:1) gave 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-
15 2-yl)-acetamino-5-benzenesulfonylamino-4-oxo-pentanoic acid, tert-butyl ester
(0.45 g).

Step H

A solution of 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
5-benzenesulfonylamino-4-hydroxy-pentanoic acid, tert-butyl ester (0.44 g,
0.48 mMol) and 15 mL of trifluoroacetic acid in 15 mL of dichloromethane was
20 stirred at room temperature for 1 hour. The solution was concentrated under
reduced pressure. Crystallization from dichloromethane/ether/hexane gave 0.17 g
of 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetamino-
5-benzenesulfonylamino-4-oxo-pentanoic acid.

25 The following compounds were also prepared according to the procedure
of Example 5 Steps F-H from the corresponding sulfonyl chlorides:

-33-

EXAMPLE 5b

(S)-5-(Bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pentanoic acid

EXAMPLE 5c

5 (S)-4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid

EXAMPLE 5d

4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-5-phenylmethanesulfonylamino-pentanoic acid

10 EXAMPLE 6a

3-[2-(2-Benzylloxycarbonylamino-4-tert-butoxycarbonyl-butyrylamino)-3-methylbutyrylamino]-5-bromo-4-oxo-pentanoic acid tert-butyl ester

A solution of Z-Glu(OtBu)ValAsp(OtBu)-OH (14.9 g, 24.6 mmol) and 4-methylmorpholine (2.7 mL, 24.6 mmol) in 200 mL of THF at ca. -40°C (dry ice CH₃CN bath) was treated with iso-butyl chloroformate (3.2 mL, 24.6 mmol). Solid immediately formed. The sample was stirred for 15 minutes, then treated with cold diazomethane (300 mL of an ether solution, freshly prepared from Diazald). The sample was stirred at room temperature for 2 hours, cooled to 0°C and quenched by dropwise addition of a 48% hydrobromic acid-acetic acid solution (35 mL of each). The ice-bath was removed, the sample was stirred at room temperature for 30 minutes, then extracted with ethyl acetate-water (500 mL of each). The organic extract was washed with water, sat. NaHCO₃ and brine solutions, dried (MgSO₄), filtered and concentrated. The residue was crystallized from dichloromethane-hexanes to give 10.5 g (63%) of 3-[2-(2-benzyl oxy-carbonylamino-4-tert-butoxycarbonyl-butyrylamino)-3-methyl-butyrylamino]-5-bromo-4-oxo-pentanoic acid tert-butyl ester (Z-Glu(OtBu)ValAsp(OtBu)CH₂Br) as a white solid.

-34-

Analysis Calculated for C₃₁H₄₆BrN₃O₉ (684.636): C, 54.39; H, 6.77; N, 6.14.

Found: C, 54.24; H, 6.63; N, 6.08.

Also prepared according to the procedure of Example 6a from the corresponding peptides were:

5

EXAMPLE 6b

3-(2-Acetylamino-3-methyl-butyrylamino)-5-bromo-4-oxo-pentanoic acid tert-butyl ester

EXAMPLE 6c

3-(2-Acetylamino-propylamino)-5-bromo-4-oxo-pentanoic acid tert-butyl ester

10

EXAMPLE 6d

3-[2-(3-Phenyl-propionylamino-4-tert-butoxycarbonyl-butyrylamino)-3-methylbutyrylamino]-5-bromo-4-oxo-pentanoic acid tert-butyl ester

EXAMPLE 6e

3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-5-bromo-4-oxo-pentanoic acid

15

INHIBITION STUDIES

Compounds of Formula I and II are inhibitors of ICE as demonstrated by measurement of K_i (μ M) and IC₅₀ (μ M) using the protocol described herein. ICE (0.24 nM final concentration) is added to 400 μ L of HGDE buffer (100 mM HEPES, 20% glycerol, 5 mM DTT, 0.5 mM EDTA) containing 15 μ M substrate (Ac-Tyr-Val-Ala-Asp-AMC; K_M = 15 μ M) plus vehicle (DMSO) or inhibitor at concentrations bracketing the K_i. Substrate hydrolysis is monitored for 300 seconds by observing the fluorescence of released AMC using excitation at 380 nm and emission at 460 nm. Mean rates of substrate hydrolysis are evaluated by linear-regression analysis of the fluorescence vs time traces. To evaluate K_i,

-35-

plots of percent inhibition vs inhibitor concentration are fit by non-linear regression to a reversible, competitive model:

$$\% \text{Inhibition} = \frac{100 * [I]}{[I] + K_i * \left(1 + \frac{[S]}{K_M}\right)}$$

where the competition factor $(1 + [S]/K_M) = 2$.

5 ICE Colorimetric Dose-Response (IC₅₀) Assay

Diluted inhibitor stocks are prepared by two-fold serial dilution from a primary stock whose concentration is selected (based on screening results or on prior attempts at IC₅₀ evaluation) to achieve approximately 95% inhibition in the most concentrated well. Aliquots of each dilution are transferred to a microtitre plate in triplicate.

10 ICE enzyme is diluted to approximately 24 nM in HGE buffer (100 mM HEPES pH 7.5, 0.5 mM EDTA, 20% glycerol, 0.1% Bovine Serum Albumin (BSA)), and activated by adding dithiothreitol (DTT) to a final concentration of 5 mM. The activated enzyme is then aliquoted into wells containing inhibitor or vehicle, and the plate is preincubated for 60 minutes at ambient temperature. Substrate (Ac-Tyr-Val-Ala-Asp-pNA) is added to each well to a final concentration of 50 μM, and plates are placed in the microtitre plate-reader thermostated to 25°C. Beginning 5 minutes after addition of substrate, absorbance (405 nm) of wells is monitored for 1 hour, and activity is calculated as the mean rate of change in absorbance during this interval.

15 20

Ich-2 (Caspase-4) Colorimetric Dose-Response (IC₅₀) Assay

Inhibition of Ich-2 enzyme is assayed as described above for ICE, except that enzyme is used at 64 nM, and 60 μM of the Ich-2-specific substrate Ac-Leu-Glu-Val-Asp-pNA is used instead of the ICE substrate Ac-Tyr-Val-Ala-Asp-pNA.

25 The results of these assays are shown below in Table 1.

-36-


TABLE 1

Example Number	ICE Ki (μ M)	ICE IC ₅₀ (μ M)	Ich-2 IC ₅₀ (Caspase-4) (μ M)
2a	11	73	96
2b	32	245	--
2c	14	168	124
2a	11.0	73.0	445.0
2b	34.5	245.0	8591.0
2c	18.0	168.0	2339.0
2d	37.0	291.0	
2e	735.0	1833.0	
2f	22.0	174.0	1008.0
2g	33.0	136.0	314.0
2h	16.0	55.6	199.0
2i	30.1	25.0	59.0
2j	65.0	194.0	159.0
2k	22.0		
2l	1.4	28.0	935.0
2m	2.8	35.3	
3a	0.007	0.072	18.0
3b	0.013	0.025	4.2
3c	0.0051	0.009	3.4
3d	0.0078	0.003	0.9
4a	0.27	7.6	
4c	0.001	0.015	8.5
4d	0.0016	0.003	1.6
4e	0.00011	0.002	0.7
4f	0.00061	0.002	3.2
5a	105.0	586.0	
5b	20.0	165.0	252.0
5c	45.0	371.0	
5d	27.0	234.0	
HEPES	=	4-(2-hydroxymethyl)-1-piperazine ethane sulfonic acid	
DTT	=	Dithiothreitol	
EDTA	=	Ethylene diamine tetra acetic acid	
AMC	=	7-amino-4-methyl coumarin	
Tyr	=	Tyrosine	
Val	=	Valine	
Ala	=	Alanine	
Asp	=	Aspartic Acid	
pNA	=	Para nitroaniline	
LEU	=	Leucine	
Glu	=	Glutamic acid	
Me	=	Methyl	
t-Bu	=	Tert butyl	

-37-


CLAIMS

1. A compound of Formula I





1

wherein R^1 is



5



R^3 is hydrogen,

C₁-C₆ alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

10 R⁴ is C₁-C₆ alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

R^5 and R^6 are each independently hydrogen,

C₁-C₆ alkyl,

15 -(CH₂)_n aryl, or

-38-

$-(CH_2)_n$ heteroaryl;

R^7 is C_1-C_6 alkyl,

$-(CH_2)_n$ aryl, or

$-(CH_2)_n$ heteroaryl;

5 each n is independently 0 to 6;


each m is independently 0, 1, 2, or 3;

A is alanine, leucine, isoleucine, proline, phenylalanine, glycine, tyrosine, serine, threonine, tryptophan, cysteine, methionine, valine, asparagine, glutamine, aspartic acid, lysine, glutamic acid, arginine,





10 or histidine;

each R^Q is independently hydrogen or C_1-C_6 alkyl;

R^2 is $-(CH_2)_n-Z$; and




Z is aryl, heteroaryl, cycloalkyl, C_1-C_6 alkyl,




15 fluorenyl, substituted fluorenyl, substituted aryl, substituted heteroaryl, or substituted cycloalkyl, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

2. A compound according to Claim 1 wherein R^1 is

-39-




3. A compound according to Claim 1 wherein R¹ is



m is 0, and R⁷ is -(CH₂)_n aryl.

- 5 4. A compound according to Claim 1 wherein R¹ is




m is 0, and R⁷ is -CH₂ aryl.

5. A compound according to Claim 1 wherein R² is -(CH₂)_n aryl.


6. A compound according to Claim 5 wherein aryl is phenyl or naphthyl.

- 10 7. A compound according to Claim 1 wherein R² is -(CH₂)_n -cycloalkyl.

8. A compound according to Claim 1 wherein R¹




9. A compound according to Claim 1 wherein R² is —CH₂—




-40-

10. A compound according to Claim 1 wherein R² is



11. A compound of the Formula I





I

wherein R² is -CH₂CH₂- aryl, -CH₂- cycloalkyl, -CH₂CH₂- cycloalkyl, or

5 -CH₂CH₂- heteroaryl;

R¹ is



R^a is -(CH₂)_n- aryl or -(CH₂)_n heteroaryl;

R^b is aryl or heteroaryl;


10 R^c is -CH₂ aryl or aryl;

R^d is hydrogen or C₁-C₆ alkyl;


R^e is -CH₂ aryl or -CH₂ heteroaryl; and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

-41-

12. A compound according to Claim 11 wherein R¹ is



13. A compound according to Claim 11 wherein R¹ is



- 5 14. A compound according to Claim 11 wherein R^e is -(CH₂)_n aryl.

15. A compound according to Claim 14 wherein aryl is phenyl or naphthyl.

16. A compound according to Claim 13 wherein R^b is aryl.

17. A compound according to Claim 16 wherein is aryl is phenyl.

18. The compounds:

10 3-Benzylcarbonylamino-4-oxo-5-(2-phenylethanesulfonylamino)-pentanoic acid;

3-Benzylcarbonylamino-4-oxo-5-(3-phenyl-propane-1-sulfonylamino)-pentanoic acid;

3-Benzylcarbonylamino-4-oxo-5-phenylmethanesulfonyl-amino-pentanoic acid;

5-Benzenesulfonylamino-3-benzylcarbonylamino-4-oxo-pentanoic acid;

3-Benzylcarbonylamino-5-methanesulfonylamino-4-oxo-pentanoic acid;

15 20 3-Benzylcarbonylamino-5-(naphthalene-1-sulfonylamino)-4-oxo-pentanoic acid;

-42-

- 3-Benzylloxycarbonylamino-5-(2-cyclohexyl-ethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-Benzylloxycarbonylamino-5-(2-naphthalen-1-yl-ethanesulfonylamino)-4-oxo-pentanoic acid;
- 5 3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(R)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-Benzylloxycarbonylamino-5-(indan-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 10 3-Benzylloxycarbonylamino-5-(9-fluoro-9H-fluoren-9-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-Benzylloxycarbonylamino-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-(2-Acetylamino-3-methyl-butrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 15 3-(2-Acetylamino-propylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-(S)-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 3-(1,2,3,4-tetrahydro-1-oxo-isoquinoline-2-yl)-acetanino-5-benzenesulfonylamino-4-oxo-pentanoic acid;
- (S)-5-(Bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pentanoic acid;
- 20 (S)-4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid; and
- 4-Oxo-3-[2-(1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-5-phenylmethanesulfonylamino-pentanoic acid.
- 25 19. A method of inhibiting interleukin-1 β converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-1 β converting enzyme a therapeutically effective amount of a compound of Claim 1.

-43-


20. A method of inhibiting Caspase-4, the method comprising administering to a patient in need of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Claim 1.
21. A method of treating or preventing stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Claim 1.
5
22. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 1.
- 10 23. The method of Claim 22 wherein the inflammatory disease is arthritis.
24. The method of Claim 22 wherein the inflammatory disease inflammatory bowel disease.
25. A pharmaceutically acceptable composition that contains a compound of Claim 1.
- 15 26. A method of inhibiting interleukin-1 β converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-1 β converting enzyme a therapeutically effective amount of a compound of Claim 11.
27. A method of inhibiting Caspase-4, the method comprising administering to a patient in need of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Claim 11.
20
28. A method of treating or preventing stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Claim 11.

-44-

29. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 11.
30. The method of Claim 29 wherein the inflammatory disease is arthritis.
- 5 31. The method of Claim 29 wherein the inflammatory disease is inflammatory bowel disease.
32. A pharmaceutically acceptable composition that contains a compound of Claim 11.
33. A method of treating septic shock, the method comprising administering to 10 a patient having septic shock a therapeutically effective amount of a compound of Claim 1.
34. A method of treating septic shock, the method comprising administering to a patient having septic shock a therapeutically effective amount of a compound of Claim 11.
- 15 35. A method of treating reperfusion injury, the method of comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 1.
36. A method of treating reperfusion injury, the method of comprising 20 administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 11.
37. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.


-45-

38. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 11.
- 5 39. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 1..
40. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 11.
- 10 41. A compound of the Formula II



wherein

R^1 is



15 R^a is $-(CH_2)_n$ - aryl or $-(CH_2)_n$ heteroaryl;

R^b is aryl or heteroaryl;

R^c is $-CH_2$ aryl or aryl;


-46-

R^d is hydrogen or C₁-C₆ alkyl;


R^e is -CH₂ aryl or -CH₂ heteroaryl; and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

42. A compound according to Claim 41 wherein R¹ is

5



43. A compound according to Claim 41 wherein R¹ is



44. A compound according to Claim 41 wherein R^e is -(CH₂)_n aryl.

45. A compound according to Claim 41 wherein aryl is phenyl or naphthyl.

- 10 46. A compound according to Claim 41 wherein R^b is aryl.

47. A compound according to Claim 46 wherein aryl is phenyl.

48. A method of inhibiting interleukin-1 β converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-1 β converting enzyme a therapeutically effective amount of a compound of Claim 41.

15

49. A method of inhibiting Caspase-4, the method comprising administering to a patient in need of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Claim 41.

-47-

50. A method of treating or preventing stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Claim 41.
51. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 41.
52. The method of Claim 51 wherein the inflammatory disease is arthritis.
53. The method of Claim 51 wherein the inflammatory disease inflammatory bowel disease.
- 10 54. A method of treating septic shock, the method comprising administering to a patient having septic shock a therapeutically effective amount of a compound of Claim 41.
55. A method of treating reperfusion injury, the method of comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 41.
- 15 56. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 41.
57. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 41.
- 20 58. The compounds:
3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;

-48-

- 3-[2-(2-Benzylloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 5 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl-butyrylamino}-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;
- 10 3-[2-(2-Benzylloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 15 3-[2-(2-Benzylloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;
- 20 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl-butyrylamino}-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid; and
 3-(2-{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-4-carboxy-butyrylamino}-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/18396

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C07C311/13	C07C311/24	C07C311/06	C07C311/10	C07K5/062
	C07K5/072	C07D217/24	A61K31/18		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 2 292 149 A (FERRING RESEARCH, ET AL.) 14 February 1996 see page 1 - page 5; claims 1,9 ---	1,19
A	WO 95 05192 A (MERCK & CO.) 23 February 1995 see page 4 - page 11; claims 1,16 ---	1,19
A	A.M.M. MJALLI, ET AL.: "Activated ketones as potent reversible inhibitors of interleukin-1 beta. converting enzyme" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 16, 1994, OXFORD, GB, pages 1965-1968, XP002053204 see the whole document --- -/-	1,19

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

3

Date of the actual completion of the international search	Date of mailing of the international search report
29 January 1998	19. 02. 98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer English, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18396

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A.M.M. MJALLI, ET AL.: "Inhibition of interleukin-1.beta. converting enzyme by N-acyl-aspartic acid ketones" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 13, 1995, OXFORD, GB, pages 1405-1408, XP002053205 see the whole document -----	1,19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/18396

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 19-24, 26-31, 33-40, 48-57
is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/18396

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2292149 A	14-02-96	NONE	
WO 9505192 A	23-02-95	AU 7714594 A	14-03-95

**CORRECTED
VERSION***

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number: WO 98/16505
C07C 311/13, 311/24, 311/06, 311/10, C07K 5/062, 5/072, C07D 217/24, A61K 31/18		(43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18396		(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.
(22) International Filing Date: 9 October 1997 (09.10.97)		
(30) Priority Data: 60/028,313 11 October 1996 (11.10.96) US		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).		
(72) Inventors; and		Published
(75) Inventors/Applicants (for US only): ALBRECHT, Hans, P. [DE/DE]; Am Wetzelsberg 59, D-69517 Goxheimertal (DE). ALLEN, Hamish, John [GB/US]; 47 Eastern Point Drive, Shrewsbury, MA 01545 (US). BRADY, Kenneth, Dale [US/US]; 32 Ivernia Road, Worcester, MA 01606 (US). HARTER, William, Glen [US/US]; 3750 Shagbark, Chelsea, MI 48118 (US). KOSTLAN, Catherine, Rose [US/US]; 9876 Moon Road, Saline, MI 48176 (US). ROTH, Bruce, David [US/US]; 49255 Hunt Club Court, Plymouth, MI 48170 (US). WALKER, Nigel [GB/DE]; Frauendorf 20, D-69221 Dossenheim (DE).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SULFONAMIDE INTERLEUKIN-1 β CONVERTING ENZYME INHIBITORS



(57) Abstract

The present invention relates to compounds that are inhibitors of interleukin-1 β converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 β converting enzyme.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		